Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
BAX · against 141 other Healthcare companies of similar size
Ranked #101 of 142 · scores higher than 26% of peers
Bars: peers in each 10-point band of the valuation score25 peers with a valuation score of 40–49, including BAX · Click a bar to see the companies
A mix: stronger free cash flow yield and EBITDA yield, but weaker earnings yield than most Healthcare peers.
| Metric | BAX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 140 reported | -7.6% | 2.7% | 3% | 30% | |
| EBITDA yieldHigher is better · 143 reported | 9.1% | 4.8% | 82% | 50% | |
| Free cash flow yieldHigher is better · 88 reported | 6.2% | 2.8% | 85% | 20% | |
| Book yieldHigher is better · 140 reported | 47.1% | 20.8% | 84% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 2 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 3 | 10.4B USD | 96 | 64 | |
| 4 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 4 | 21.5B USD | 95 | 60 | |
| 98 | 1.77T INR (≈$21.2B) | 43 | 57 | |
| 101 | 64.1B CNY (≈$9.0B) | 41 | 48 | |
| 101 | 7.7B USD | 41 | 37 | |
| 101 | 593.2B INR (≈$7.1B) | 41 | 47 | |
| 101 | 13.2B USD | 41 | 30 | |
| 101 | 10.8B USD | 41 | 41 | |
| 101 | 12.6B USD | 41 | 65 | |
| 107 | 7.3B USD | 40 | 74 | |
| 108 | 138.4B HKD (≈$17.7B) | 39 | 70 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score